Illumina Is Shrinking Again. The Reason Why Should Worry Every Sequencing Company.
Illumina just axed 300+ jobs as part of a $100 million cost-cutting plan, bringing total layoffs since 2022 to roughly 1,000. But the real story isn't one company's restructuring; it's a sequencing industry where competitors like Ultima Genomics are delivering $80 genomes and Element Biosciences is undercutting Illumina's reagent prices by two-thirds.
The Bellwether Is Bleeding
Illumina just cut more than 300 jobs. That's roughly 3.5% of the company's workforce, gone in a single stroke. And if you're thinking this sounds familiar, you're right: the genomics giant has now let go of approximately 1,000 employees since late 2022.
But this isn't a story about one company having a bad quarter. It's a story about an entire industry being reshaped by forces that didn't exist five years ago. When the biggest name in DNA sequencing keeps trimming headcount, it tells you something about where the market is headed.
Death by a Thousand Competitors
For years, Illumina was the sequencing industry's undisputed heavyweight. If you wanted to read a genome, you bought an Illumina machine. Full stop. That dominance let the company charge premium prices and enjoy fat margins.
Those days are fading fast.
Consider what's happened to the competitive landscape. Ultima Genomics now offers whole genome sequencing for roughly $80 per genome, undercutting Illumina's NovaSeq X, which runs around $200 per genome in consumable costs. That's not a rounding error; it's a fundamentally different price point.
Then there's Element Biosciences, which is attacking Illumina from a different angle. Element's benchtop sequencer (the AVITI) costs about $289,000, compared to $335,000 for Illumina's competing NextSeq. The real pain, though, is in consumables: Element's reagent kits run roughly one-third the price of Illumina's comparable kits. Element claims labs switching from NextSeq to AVITI can save about $1.5 million over three years, even if the NextSeq were given to them for free.
And we haven't even mentioned Oxford Nanopore, whose long-read technology is approaching price parity with short-read sequencing on a per-genome basis. Or Singular Genomics, which competes on workflow flexibility. Illumina suddenly finds itself surrounded.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Think of it like a restaurant that was the only place in town for years. The food was great, sure, but the prices reflected zero competition. Now three new restaurants have opened on the same block, each with a different angle: one is cheaper, one is faster, one has a more creative menu. The original place still has loyal regulars, but new customers have options.
The $100 Million Diet
These latest cuts aren't a panic move. They're part of a deliberate, ongoing plan to slash $100 million in annual recurring costs. CEO Jacob Thaysen, who took the helm in September 2023, has framed the restructuring as a multi-year transformation with clear financial targets: roughly 500 basis points of operating margin expansion by 2027 and annual earnings-per-share growth in the low double digits.
The playbook includes more than just layoffs. Illumina is exiting its "i3" campus in San Diego, partially vacating its Foster City facility, and streamlining R&D operations across sites in Madison, Singapore, and the U.K. The R&D team alone reportedly took a 10% haircut in an earlier round of cuts.
Illumina's 2025 revenue came in at about $4.34 billion, essentially flat year over year. For 2026, management guided to $4.5 to $4.6 billion and later nudged that up slightly to $4.52 to $4.62 billion after a decent start to the year. Growth is happening, but it's the kind of modest single-digit expansion that doesn't exactly inspire Wall Street to pop champagne.
The China problem isn't helping. Illumina's ex-China revenue grew about 2% in 2025, which means China was actively dragging down the overall number. Restrictions and geopolitical headwinds in the region continue to cloud the outlook.
Wall Street's Verdict: Show Me
Analysts have been politely skeptical. In past rounds of Illumina job cuts, the stock has typically dipped a few percent on the news before settling back into a holding pattern. The consensus view: cost discipline is welcome, but it doesn't fix the demand problem.
Historically, when Illumina has paired layoff announcements with weaker guidance, the reaction has been sharper, triggering many analysts to cut their price targets while keeping their ratings at neutral. The message from Wall Street is essentially: "We'll believe the turnaround when we see it in the revenue line, not just the expense line."
There's also a quieter concern about cutting too deep. Slashing R&D headcount and tightening stock-based compensation could push top talent out the door. In genomics, where your next product is only as good as the scientists building it, that's a dangerous game.
It's Not Just Illumina
Zoom out and you'll see that Illumina is part of a much larger pattern. Life sciences layoffs in 2026 are fewer in number but bigger in scale compared to prior years. Fierce Biotech tracked 33 biopharma companies laying off or shutting down in Q1 2026, about half the 63 rounds in Q1 2025.
But the people affected per event are climbing. Takeda is targeting roughly 4,500 roles globally. BioNTech is cutting about 1,860 jobs as it pivots from COVID vaccines to oncology. Novo Nordisk plans to eliminate around 9,000 positions worldwide. Merck is trimming its global workforce by approximately 8%.
The industry has shifted from emergency cost-cutting (the 2022-2024 era of rising rates and frozen IPOs) to what analysts call "structured workforce optimization." Translation: companies aren't panicking anymore, but they're methodically reshaping themselves for a leaner future.
For smaller biotechs, the pain is more binary. Clinical trial failures and FDA rejections still trigger brutal cuts. BioAtla eliminated roughly 70% of its workforce in March. Theravance halved its staff. Several companies simply shut down entirely.
What This Means for the Sequencing Wars
Illumina's restructuring is ultimately a bet that the sequencing market's future rewards ecosystem lock-in and workflow integration more than raw cost-per-gigabase. The company still has the largest installed base, the broadest clinical validation, and the deepest bioinformatics stack. Those advantages are real.
But the pricing power that funded Illumina's golden era is eroding from every direction. Ultima is setting the floor at the high-throughput end. Element is squeezing margins in the benchtop tier. Oxford Nanopore is making long-read sequencing (which captures information that short-read can't) affordable enough to steal certain applications entirely.
Illumina isn't going away. It's still a $4.5 billion revenue company with technology that millions of researchers depend on. But the era of comfortable dominance is over, and the job cuts are the clearest proof. When the king starts tightening its belt, every duke and baron in the kingdom should pay attention.
Clinical & Regulatory
5 min read
Prostate Cancer Just Got Its HER2 Moment
The FDA just approved the first targeted therapy for a specific genetic subtype of prostate cancer, turning PTEN loss from a bad prognosis into an actionable target. It's the same precision oncology playbook that transformed breast cancer, and it could reshape how we treat the most common male cancer.
